When is the next results date for Vista Pharmaceuticals Ltd?
2026-05-20 23:17:41The next results date for Vista Pharmaceuticals Ltd is scheduled for 29 May 2026....
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-05-20 10:10:21Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 20 May 2026, providing investors with the latest insights into its performance and prospects.
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-05-07 10:10:27Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 Jul 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-04-26 10:10:13Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-04-15 10:10:17Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-04-03 10:10:14Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 03 April 2026, providing investors with the latest insights into its performance and prospects.
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-03-19 10:10:20Vista Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.5.71
2026-03-09 11:27:42Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions.
Read full news article
Vista Pharmaceuticals Ltd is Rated Strong Sell
2026-03-05 10:10:20Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleBoard Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2026
19-May-2026 | Source : BSEVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.2026 2. Audit Report for the quarter and year ended 31.03.2026 3. Any other business with the permission of the Chair.
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29-Apr-2026 | Source : BSEFormat of the Annual Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Vista Pharmaceuticals Ltd |
| 2 | CIN NO. | L24239TG1991PLC012264 |
| 3 | Report filed for FY | 2025-2026 |
| Details of the Current block (all figures in Rs crore): | ||
| 4 | 2 - year block period (Specify financial years)* | 2025-26 2026-27 |
| 5 | Incremental borrowing done in FY (T)(a) | 0.00 |
| 6 | Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) | 0.00 |
| 7 | Actual borrowing done through debt securities in FY (T)(c) | 0.00 |
| 8 | Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) | 0 |
| 8 | Quantum of (d) which has been met from (c)(e)* | 0 |
| 9 | Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* | 0 |
| Details of penalty to be paid if any in respect to previous block (all figures in Rs crore): | |
| 2 - year Block period (Specify financial years) | 2024-25 2025-26 |
| Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}# | 0.00 |
| Name of the Company Secretary :- | Barka Jain |
| Designation :- | Company Secretary compliance Officer |
| Name of the Chief Financial Officer :- | Suneel pachipala |
| Designation : - | CFO |
Date: 29/04/2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Apr-2026 | Source : BSECompliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
Corporate Actions
29 May 2026
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






